MassMutual Private Wealth & Trust FSB lowered its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 47,931 shares of the medical research company's stock after selling 3,514 shares during the period. MassMutual Private Wealth & Trust FSB's holdings in Thermo Fisher Scientific were worth $24,935,000 at the end of the most recent quarter.
A number of other hedge funds also recently added to or reduced their stakes in the stock. Intech Investment Management LLC increased its stake in shares of Thermo Fisher Scientific by 19.4% during the second quarter. Intech Investment Management LLC now owns 3,142 shares of the medical research company's stock valued at $1,738,000 after acquiring an additional 510 shares during the period. Pacer Advisors Inc. grew its position in Thermo Fisher Scientific by 6.2% during the 2nd quarter. Pacer Advisors Inc. now owns 28,900 shares of the medical research company's stock worth $15,982,000 after purchasing an additional 1,685 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Thermo Fisher Scientific by 5.5% in the second quarter. Thrivent Financial for Lutherans now owns 119,619 shares of the medical research company's stock worth $66,148,000 after purchasing an additional 6,185 shares in the last quarter. Summit Trail Advisors LLC boosted its position in Thermo Fisher Scientific by 3.9% during the second quarter. Summit Trail Advisors LLC now owns 4,164 shares of the medical research company's stock valued at $2,304,000 after purchasing an additional 157 shares during the last quarter. Finally, Westwood Holdings Group Inc. grew its stake in shares of Thermo Fisher Scientific by 80.5% in the 2nd quarter. Westwood Holdings Group Inc. now owns 2,226 shares of the medical research company's stock valued at $1,231,000 after buying an additional 993 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities analysts have commented on TMO shares. Morgan Stanley lowered their target price on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an "overweight" rating on the stock in a research report on Monday, January 13th. StockNews.com upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. Scotiabank began coverage on Thermo Fisher Scientific in a report on Monday, December 23rd. They set a "sector perform" rating and a $605.00 price objective on the stock. Bernstein Bank raised their price target on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a report on Tuesday, October 22nd. Finally, Barclays cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an "equal weight" rating on the stock in a report on Wednesday, October 23rd. Four research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $648.95.
Read Our Latest Stock Report on TMO
Thermo Fisher Scientific Stock Down 0.4 %
Shares of TMO stock traded down $1.99 during trading on Monday, reaching $559.72. The company's stock had a trading volume of 2,134,669 shares, compared to its average volume of 1,426,114. The company has a market cap of $214.09 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 3.59 and a beta of 0.76. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The business has a fifty day moving average price of $529.96 and a 200-day moving average price of $568.56. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The company had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.69 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 earnings per share for the current year.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.
Thermo Fisher Scientific declared that its board has approved a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.
Insider Buying and Selling at Thermo Fisher Scientific
In other news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $1,120,320.00. Following the transaction, the senior vice president now owns 12,736 shares of the company's stock, valued at approximately $7,134,197.76. This represents a 13.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total value of $168,048.00. Following the sale, the executive vice president now directly owns 16,663 shares of the company's stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last ninety days. Insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Featured Articles
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
